Strategic Partnerships Imaginostics has FDA Breakthrough Device Designation and a non-exclusive partnership with Siemens Healthineers, plus ongoing collaboration potential with Mayo Clinic Ventures. This signals strong credibility and a clear path for co-development, integration with existing clinical workflows, and rapid pilot opportunities in hospital systems.

Clinical Validation A 96-patient biomarker study in motion and recognition at MedTech awards underscore robustness of the vascular imaging platform. Use these factors to craft case studies and ROI scenarios for hospitals and health systems prioritizing evidence-based adoption and preventive neurology programs.

Hospital Market Focus The technology transforms standard MRI scanners into quantitative diagnostic tools, appealing to hospitals aiming to upgrade diagnostic precision without new hardware. Target radiology and oncology departments seeking enhanced brain cancer, Alzheimer's, and neurodegeneration insights with minimal capital expenditure.

Strategic Events Active presence at Mayo Clinic Summit, Florida Early Venture Conference, Startup Olé, eMerge Americas, and other notable events indicates opportunities to engage decision-makers, secure speaking slots, and set up pilot discussions during high-visibility gatherings.

Scale & Funding Readiness Revenue range and $8.5M funding position Imaginostics as a lean, high-p impact vendor with potential for multi-site deployments. Use this to frame scalable deployment models, phased pilots, and preferred vendor status with health networks seeking innovative, cost-effective imaging biomarkers.